Roche reported third-quarter group sales of 16.13 billion Swiss francs ($19.57 billion). That exceeded the average analyst forecast of 15.78 billion francs. Sales rose 7% at constant exchange rates.
Demand for Ocrevus, Roche’s multiple sclerosis treatment, and Hemlibra, its hemophilia medicine, supported growth in the pharmaceuticals division. Division sales increased 8%. Diagnostics sales rose 5%.
Roche confirmed its full-year guidance.